Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Larimar Therapeutics Inc LRMR

Healthcare Biotechnology
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd... see more

Current News (NDAQ:LRMR)

Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 18, 2025

Larimar Therapeutics Reports Third Quarter 2025 Financial Results

GlobeNewswire November 5, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

ACCESS Newswire November 2, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

ACCESS Newswire November 1, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Larimar Therapeutics, Inc. (LRMR) And Encourages Shareholders to Reach Out

ACCESS Newswire October 31, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

ACCESS Newswire October 31, 2025

Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - LRMR

Business Wire October 30, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

ACCESS Newswire October 30, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Larimar Therapeutics, Inc. (LRMR) and Encourages Shareholders to Learn More About the Investigation

ACCESS Newswire October 30, 2025
View More News ››

Opinion & Analysis (NDAQ:LRMR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LRMR)

Buy buddy buy.

Otherwise FOMO for you fellas out there today anyway so good luck to all shareholders
coolfooldumbguy - August 5, 2025

Biopharmaceutical Zafgen (ZFGN) Trading 44% Below Cash Value

Zafgen (NASDAQ:ZFGN) anounnced on 7/19/2016 that in order to concentrate effort and resources, it will drop one trial...
MiamiGent - July 24, 2016
View more Bullboard ››

Alvopetro Energy Ltd.

Alvopetro Energy Ltd.

Alvopetro Energy Ltd. engages in the acquisition, exploration, development, and production of hydrocarbons in Brazil and ...
View More »

Podcasts